RankAlpha logo
Back to Rankings

URGN

UroGenD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
View Chart
Current thesis
The supported bull case is that UroGen now has two meaningful value drivers at once: ZUSDURI reimbursement friction improved after the January 1, 2026 J-code effective date, and UGN-103 has a defined regulatory path after the UTOPIA data. If launch metrics keep compounding and the NDA timeline holds, the stock has room to move toward a more development-plus-commercial multiple.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -1.3.
What can break
Cash, cash equivalents, and marketable securities were $120.5 million at December 31, 2025, while net loss was $153.5 million for 2025, keeping funding and cash-burn monitoring important.
Momentum
96
Value
41
Sentiment
6
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $27.00 · Bull $33.00 · Bear $16.00
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-01 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $44.75
Why
Momentum96 · Δ7d -1.3
Value41 · Δ7d +0.1
Sentiment6 · Δ7d -3.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
96
26% active weight
Current posture
7d trendSoftening
Δ7d
-1.3
Δ21d
+4.9
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
6
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.2
Δ21d
-11.3
Why this grade

Composite grade D. Momentum 96.0 / Value 41.1 / Sentiment 6.3

Fundamentals (TTM)
As of 2026-07-21
Market Cap
$2.13B
Beta
1.35
Shares Out
48.72M
P/E (TTM) · Derived
-13.7
P/S (TTM)
10.73
P/FCF (TTM) · Derived
-12.09
Rev YoY
+151.6%
EPS YoY
-49.2%
Gross Margin
+89.9%
Op Margin
-138.2%
Net Debt
$8.28M
Current Ratio
4.69
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology